Study wrapper · #1076
Atypical Anorexia Nervosa Developed in a Patient with Severe Obesity and Type 2 Diabetes Following Sleeve Gastrectomy and Postoperative Treatment with Semaglutide and Tirzepatide.
Saito C, Saito M, Nakagawa M, et al. Internal medicine (Tokyo, Japan). 2026.
DOI: 10.2169/internalmedicine.7502-26PubMed: 42543696
Editor's note
A single case cannot establish causation, and this patient also underwent sleeve gastrectomy, making the peptides' specific contribution impossible to isolate. It is a useful safety-awareness signal that rapid weight loss regimens may coincide with disordered-eating psychopathology in susceptible individuals. Regard it as hypothesis-generating rather than as evidence of a defined risk.
Plain-language abstract
This single case report describes a 60-year-old woman who developed atypical anorexia nervosa after bariatric surgery combined with semaglutide and tirzepatide. The authors note the co-occurrence but cannot establish that the medications were the cause.
Related coverage
Mixed
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
Journal of obstetrics and gynaecologyn=——2026
Weak / none
A qualitative study exploring experiences about using semaglutide for weight loss in a rural setting in Denmark - 'she is probably on the meds'.
Scandinavian journal of primary health caren=——2026
Mixed
GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers.
Annals of medicinen=——2026